Lv51
1370 积分 2022-04-13 加入
Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice
13分钟前
已完结
Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents
37分钟前
已完结
ABT, Elacridar and Bile‐Duct Cannulated Rats: Tools to Understand Pharmacokinetics
1小时前
已完结
Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility
2个月前
已完结
Elucidating Molecular Mechanisms of Drug-Induced Hepatotoxicity of Lapatinib
2个月前
已完结
Halogenation-Driven Discovery of Halomethylene-Biphenyl-Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Safety and PK Profiles
2个月前
已完结
OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys
3个月前
已关闭
Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part I. Selection of an Evans Auxiliary-Assisted Asymmetric 1,4-Addition Route
3个月前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
3个月前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
3个月前
已完结
皖公网安备34019202002308
